

Contents

I Mechanism of hormonal action at cellular level and biochemistry

Mechanism and effects of androgen withdrawal therapies N. Bruchofsky, P. S. Rennie, S. L. Goldenberg	3
Target-cell response to androgen withdrawal K. D. Voigt, H. Klein	15
Effects of chronic treatment with an LH-RH agonist on human testis tissue I. T. Huhtaniemi	19
Animal models for prostate cancer U. Otto, B. Wagner, G. Klöppel, H. Baisch, H. Klosterhalfen	29
The significance of the nude mice model for studies on human prostatic carcinoma G. J. van Steenbrugge, F. H. de Jong, M. P. W. Gallee, F. H. Schröder	39

II Etiology and experimental basis of therapy

Etiology and natural history of early prostatic cancer F. H. Schröder	49
Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists F. Neumann, M. F. El Etreby, U.-F. Habenicht, A. Radlmaier, K. Bormacher	57

III Clinics

Evaluation of different endocrine approaches in the treatment of prostatic carcinoma A. O. Turkes, W. B. Peeling, D. W. Wilson, K. Griffiths	75
Rationale of total androgen blockade by cyproterone acetate U. W. Tunn	87

Clinical experience with Androcur® in the treatment of prostatic cancer H. Becker, H. Klosterhalfen	97
Prostate cancer treatment: tolerance of different endocrine regimens E. Varenhorst	105
Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients F. Di Silverio, F. Sciarra	115
Results and experience with the androgen ablation therapy: current trends in the USA D. Kirchheim	121
Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate G. H. Jacobi	127
List of first mentioned contributors	138